Download PDF
Viszeralchirurgie 2000; 35(2): 124-130
DOI: 10.1055/s-2000-12046
ORIGINALARBEIT
Georg Thieme Verlag Stuttgart · New York

Anämie in der Chirurgie

K. Buttenschoen1 , D. C. Buttenschoen2
  • 1Chirurgische Klinik I, Universität Ulm
  • 2Klinik für Anästhesiologie, Universität Ulm
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

Zusammenfassung.

Die Anämie ist eine häufige Begleiterscheinung in der Chirurgie. Bei mangelnder Versorgung des Organismus mit Sauerstoff und unzureichender kardiopulmonaler Kompensation können vor allem im zentralen Nervensystem und Myokard irreversible Gewebeschäden entstehen. Bluttransfusionen können dieses Risiko vermindern, aber es besteht die Gefahr der Übertragung von Infektionskrankheiten und Immunreaktionen. Durch die Bereitstellung von Eigenblut, intraoperative Retransfusion von Wundblut, blutsparende Operationstechniken, Hämodilution und Medikamente konnte der Verbrauch von allogenem Blut (= Fremdblut) vermindert werden. Allogene Blutprodukte sind aber mittlerweile sehr sicher geworden und limitieren daher den Therapievorteil des Eigenblutes. Die Verwendung von Eigenblut ist außerdem teurer als allogenes Blut und dem breiten Einsatz von Erythropoetin stehen noch die hohen Kosten entgegen. Limitierte Ressourcen zwingen zur Ökonomie. Sichere Erkenntnisse zur differenzierten Transfusionstherapie sind rar und es existiert keine allgemeingültige Transfusionsschwelle. Bei chirurgischen Patienten ohne Risikofaktoren scheint die angemessene Transfusionsschwelle bei 80 g/L (8 g/dl) zu liegen, während bei Patienten mit Risikofaktoren 100 g/L (10 g/dl) gerechtfertigt erscheinen. Die Transfusionsschwelle ist für jeden Patienten in Abhängigkeit der Grunderkrankung und Komorbidität individuell festzulegen. Prophylaktische Transfusionen sind abzulehnen, da sie bei kritisch Kranken zu unerwünschten Nebenwirkungen führen können.

Übersetzung fehlt.

Anemia occurs frequently in surgical patients. Reduced oxygen delivery and insufficient cardiopulmonary compensation can induce irreversible tissue damage particularly in the central nervous system and the myocardium. Blood transfusion can reduce this risk but there's a danger to transmit infectious diseases and to induce immune reactions. Preoperative autologous blood donation, intraoperative retransfusion of wound blood, blood saving surgical techniques, hemodilution and drugs reduced the use of allogenic blood. Meanwhile, safety of allogenic blood improved substantially causing limited therapeutic advantage of autologous blood. The use of autologous blood is more expensive than allogenic blood, high costs of erythropoietin hinders its broad use, and limited funds necessitate economy. However, valid knowledge for a well-differentiated transfusion therapy is rare and there is no general applicable threshold for transfusion at which the benefits outweigh the risks. A hemoglobin level of 80 g/L (8 g/dl) seems an appropriate threshold for transfusion in surgical patients with no risk factors for ischemia, whereas a threshold of 100 g/L (10 g/dl) can be justified for patients who are considered at risk. The threshold for transfusion varies individually dependent on disease and comorbidity. Prophylactic transfusion cannot be endorsed since overuse in patients undergoing cardiac surgery and critically ill patients may be associated with less favorable outcomes.

Schlüsselwörter:

Anämie - Chirurgie - Bluttransfusion - Transfusionsrisiko - Transfusionsschwelle - Erythropoetin.

Key words:

Anemia - surgery - blood transfusion - transfusion risk - transfusion threshold - erythropoietin.

Literatur

  • 1 Adamson J. Perisurgical use of epoetin alfa in orthopedic surgery patients.  Semin Hematol. 1996;  33 55-58
    PubMedGoogle Scholar
  • 2 American College of Physicians . Practice strategies for elective red blood cell transfusion.  Ann Intern Med. 1992;  116 403-406
    PubMedGoogle Scholar
  • 3 Atabek U, Alvarez R, Pello M J. et al . Erythropoetin accelerates hematocrit recovery in post-surgical anemia.  Am Surg. 1995;  61 74-77
    PubMedGoogle Scholar
  • 4 Atlas S J, Singer D E, Skates S J. Changing blood use in the AIDS era: the case of elective hip surgery.  Transfusion. 1994;  34 386-391
    CrossrefPubMedGoogle Scholar
  • 5 AuBuchon J P. Cost-effectiveness of preoperative autologous blood donation for orthopedic and cardiac surgeries.  Am J Med. 1996;  101 S38-S42
    CrossrefPubMedGoogle Scholar
  • 6 Audet A M, Andrzejewski C, Popovsky M A. Red blood cell transfusion practices in patients undergoing orthopedic surgery: a multi-institutional analysis.  Orthopedics. 1998;  21 851-858
    PubMedGoogle Scholar
  • 7 Baudoux E. Autologous blood donation plus epoetin alfa in nonanemic orthopedic surgery patients.  Semin Hematol. 1997;  33 31-32
    PubMedGoogle Scholar
  • 8 Baxter B T, Minion D J, McCance C L, Eskildsen J M, Heffele J J, Lynch T G. Rational approach to postoperative transfusion in high-risk patients.  Am J Surg. 1993;  166 720-724
    PubMedGoogle Scholar
  • 9 Beris P. Epoetin alfa as an adjuvant to autologous blood donation.  Semin Hematol. 1996;  33 27-30
    PubMedGoogle Scholar
  • 10 Beris P, Mermillod B, Levy G. et al . Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study.  Vox Sang. 1993;  65 212-218
    PubMedGoogle Scholar
  • 11 Biesma D H, Marx J J, Kraaijenhagen R J, Franke W, Messinger D, van-de Wiel A. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin.  Lancet. 1994;  344 367-370
    CrossrefPubMedGoogle Scholar
  • 12 Blumberg N, Heal J M. Transfusion and host defenses against cancer recurrence and infection.  Transfusion. 1989;  29 236-245
    CrossrefPubMedGoogle Scholar
  • 13 Bordin J O, Heddle N M, Blajchman M A. Biologic effects of leukocytes present in transfused cellular blood products.  Blood. 1994;  84 1703-1721
    PubMedGoogle Scholar
  • 14 Bose W J. The potential use of human recombinant erythropoietin in orthopedic surgery.  Orthopedics. 1996;  19 325-328
    PubMedGoogle Scholar
  • 15 Braga M, Gianotti L, Gentilini O, Vignali A, Di C V. Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery.  Hepatogastroenterology. 1997;  44 685-690
    PubMedGoogle Scholar
  • 16 Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrent rate.  Lancet. 1982;  2 662
    PubMedGoogle Scholar
  • 17 Busch O R, Hop W C, Hoynck van P M, Marquet R L, Jeekel J. Blood transfusions and prognosis in colorectal cancer.  N Engl J Med. 1993;  328 1372-1376
    CrossrefPubMedGoogle Scholar
  • 18 Canadian Orthopedic Perioperative Erythropoietin Study Group . Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement.  Lancet. 1993;  341 1227-1232
    PubMedGoogle Scholar
  • 19 Carson J L, Duff A, Berlin J A. et al . Perioperative blood transfusion and postoperative mortality.  JAMA. 1998;  279 199-205
    CrossrefPubMedGoogle Scholar
  • 20 Carson J L, Duff A, Poses R M. et al . Effect of anaemia and cardiovascular disease on surgical mortality and morbidity.  Lancet. 1996;  348 1055-1060
    CrossrefPubMedGoogle Scholar
  • 21 Carson J L, Terrin M L, Barton F B. et al . A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture.  Transfusion. 1998;  38 522-529
    CrossrefPubMedGoogle Scholar
  • 22 Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer (Hrsg). Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten.  Köln; Deutscher Ärzte-Verlag 1995
    Google Scholar
  • 23 Churchill W H, McGurk S, Chapman R H. et al . The Collaborative Hospital Transfusion Study: variations in use of autologous blood account for hospital differences in red cell use during primary hip and knee surgery.  Transfusion. 1998;  38 530-539
    CrossrefPubMedGoogle Scholar
  • 24 Consensus Conference. Perioperative red blood cell transfusion. JAMA 1988 260: 2700-2703
    Google Scholar
  • 25 Danko J, Huch R, Huch A. Epoetin alfa for treatment of postpartum anaemia.  Lancet. 1990;  335 737-738
    PubMedGoogle Scholar
  • 26 deAndrade J R. Prudent strategies for red blood cell conservation in orthopedic surgery.  Am J Med. 1996;  101 S16-S21
    CrossrefPubMedGoogle Scholar
  • 27 dePree C, Mermillod B, Hoffmeyer P, Beris P. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation in elective surgery with large blood needs (> or = 5 units): a randomized study.  Transfusion. 1997;  37 708-714
    CrossrefPubMedGoogle Scholar
  • 28 Dodd R Y. The risk of transfusion-transmitted infection.  N Engl J Med. 1992;  327 419-421
    PubMedGoogle Scholar
  • 29 Etchason J, Petz L, Keeler E. et al . The cost effectiveness of preoperative autologous blood donations.  N Engl J Med. 1995;  332 719-724
    CrossrefPubMedGoogle Scholar
  • 30 Expert Working Group . Guidelines for red blood cell and plasma transfusions for adults and children.  Can Med Assoc J. 1997;  156 S1-S24
    PubMedGoogle Scholar
  • 31 Flegel W A. Transfusion. In: Delves PJ, Roitt IM (Hrsg.) Encyclopedia of Immunology.  San Diego; Academic Press 1998: 2399
    Google Scholar
  • 32 Flegel W A, Koerner K, Wagner F F, Kubanek B. Zehn Jahre HIV-Testung in den Blutspendediensten.  Dt Ärztebl. 1996;  93 A816-A821
    PubMedGoogle Scholar
  • 33 Fleming A, Bishop M, Shoemaker W. et al . Prospective trial of supranormal values as goals of resuscitation in severe trauma.  Arch Surg. 1992;  127 1175-1179
    PubMedGoogle Scholar
  • 34 Ford C D, VanMoorleghem G, Menlove R L. Blood transfusions and postoperative wound infection.  Surgery. 1993;  113 603-607
    PubMedGoogle Scholar
  • 35 Georgieff M, Schirmer U (Hrsg.) Klinische Anästhesiologie.  Berlin; Springer 1995
    Google Scholar
  • 36 Glück D, Kubanek B, Maurer C, Petersen N. Seroconversion of HIV, HCV, and HBV in Blood Donors in 1996 - Risk of Virus Transmission by Blood Products in Germany.  Infusionsther Transfusionsmed. 1998;  25 82-84
    CrossrefPubMedGoogle Scholar
  • 37 Goodnough L T, Brecher M E, Kanter M H, AuBuchon J P. Blood conservation.  N Engl J Med. 1999;  340 525-533
    CrossrefPubMedGoogle Scholar
  • 38 Goodnough L T, Brecher M E, Kanter M H, AuBuchon J P. Blood transfusion.  N Engl J Med. 1999;  340 438-447
    CrossrefPubMedGoogle Scholar
  • 39 Goodnough L T, Rudnick S, Price T H. et al . Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy.  N Engl J Med. 1989;  321 1163-1168
    CrossrefPubMedGoogle Scholar
  • 40 Goodnough L T, Soegiarso R W, Geha A S. Blood lost and blood transfused in coronary artery bypass graft operation as implications for blood transfusion and blood conservation strategies.  Surg Gynecol Obstet. 1993;  177 345-351
    PubMedGoogle Scholar
  • 41 Greenburg A G. Pathophysiology of anemia.  Am J Med. 1996;  101 7S-11S
    CrossrefPubMedGoogle Scholar
  • 42 Hebert P C, Wells G, Tweeddale M. et al . Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group.  Am J Respir Crit Care Med. 1997;  155 1618-1623
    PubMedGoogle Scholar
  • 43 Heiss M M, Mempel W, Delanoff C. et al . Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery.  J Clin Oncol. 1994;  12 1859-1867
    PubMedGoogle Scholar
  • 44 Hogue C W, Goodnough L T, Monk T G. Perioperative myocardial ischemic episodes are related to hematocrit level in patients undergoing radical prostatectomy.  Transfusion. 1998;  38 924-931
    CrossrefPubMedGoogle Scholar
  • 45 Houbiers J GA, Brand A, van-de Watering L MG. et al . Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer.  Lancet. 1994;  344 573-578
    CrossrefPubMedGoogle Scholar
  • 46 Jensen L S, Andersen A J, Christiansen P M. et al . Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery.  Br J Surg. 1992;  79 513-516
    PubMedGoogle Scholar
  • 47 Jensen L S, Kissmeyer N P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery.  Lancet. 1996;  348 841-845
    CrossrefPubMedGoogle Scholar
  • 48 Johnson R G, Thurer R L, Kruskall M S. et al . Comparison of two transfusion strategies after elective operations for myocardial revascularization.  J Thorac Cardiovasc Surg. 1992;  104 307-314
    PubMedGoogle Scholar
  • 49 Kasper S M, Grune F, Walter M, Amr N, Erasmi H, Buzello W. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery.  Anesth Analg. 1998;  87 284-291
    CrossrefPubMedGoogle Scholar
  • 50 Koch K. Künstliche Blutersatzstoffe; Hoffnungsträger ist gescheitert.  Dt Ärztebl. 1999;  96 B-352
    PubMedGoogle Scholar
  • 51 Kubanek B, Wagner F. Therapie mit Erythrozyten. In: Mueller-Eckhardt C (Hrsg.) Transfusionsmedizin.  Berlin und Heidelberg; Springer 1996: 321
    Google Scholar
  • 52 Lagaaij E L, Hennemann I P, Ruigrok M. et al . Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts.  N Engl J Med. 1989;  321 701-705
    PubMedGoogle Scholar
  • 53 Larocque B J, Gilbert K, Brien W F. A point score system for predicting the likelihood of blood transfusion after hip or knee arthroplasty.  Transfusion. 1997;  37 463-467
    CrossrefPubMedGoogle Scholar
  • 54 Larocque B J, Gilbert K, Brien W F. Prospective validation of a point score system for predicting blood transfusion following hip or knee replacement.  Transfusion. 1998;  38 932-937
    CrossrefPubMedGoogle Scholar
  • 55 Laupacis A. Effectiveness of perioperative epoetin alfa in patients scheduled for elective hip surgery.  Semin Hematol. 1996;  33 51-53
    PubMedGoogle Scholar
  • 56 Löwer J. Bekanntmachung des Paul-Ehrlich-Instituts vom 25. 02. 1998 und 05. 06. 1998. Paul-Ehrlich-Institut 1998
    Google Scholar
  • 57 McSwiney M M, O'Farrell D, Joshi G P, McCarroll S M. Blood transfusion in total hip arthroplasty: guidelines to eliminate overtransfusion.  Can J Anaesth. 1993;  40 222-226
    PubMedGoogle Scholar
  • 58 Mercuriali F, Zanella A, Barosi G. et al . Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients.  Transfusion. 1993;  33 55-60
    CrossrefPubMedGoogle Scholar
  • 59 Mitglieder des Bundesgerichtshofes und der Bundesanwaltschaft .AZ BGH VI ZR 40/91; Urteil vom 17. 12. 91, Hepatitis und AIDS durch Bluttransfusion.  Köln; Heymanns 1992: 379
    Google Scholar
  • 60 Mohini R. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.  Semin Nephrol. 1989;  9 16-21
    PubMedGoogle Scholar
  • 61 Nelson A H, Fleisher L A, Rosenbaum S H. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit.  Crit Care Med. 1993;  21 860-866
    PubMedGoogle Scholar
  • 62 Opelz G, Vanrenterghem Y, Kirste G. et al . Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients.  Transplantation. 1997;  63 964-967
    PubMedGoogle Scholar
  • 63 Robert Koch-Institut . Bekanntmachungen: Stellungsnahme des Arbeitskreises Blut des Bundesministeriums für Gesundheit „Filtration von zellulären Blutpräparaten”.  Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitschutz. 1999;  42 89-92
    PubMedGoogle Scholar
  • 64 Rutherford C J, Kaplan H S. Autologous blood donation - can we bank on it?.  N Engl J Med. 1995;  332 740-742
    CrossrefPubMedGoogle Scholar
  • 65 Sheffield R, Sullivan S D, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia.  Ann Pharmacother. 1997;  31 15-22
    PubMedGoogle Scholar
  • 66 Shoemaker W C, Appel P L, Kram H B. Hemodynamic and oxygen transport responses in survivors and nonsurvivors of high-risk surgery.  Crit Care Med. 1993;  21 977-990
    CrossrefPubMedGoogle Scholar
  • 67 Sobota J T. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.  Contrib Nephrol. 1989;  76 166-178
    PubMedGoogle Scholar
  • 68 Spence R K, Cernaianu A C, Carson J, DelRossi A J. Transfusion and surgery.  Curr Probl Surg. 1993;  30 1101-1180
    PubMedGoogle Scholar
  • 69 Stehling L, Simon T L. The red blood cell transfusion trigger. Physiology and clinical studies.  Arch Pathol Lab Med. 1994;  118 429-434
    PubMedGoogle Scholar
  • 70 Stover E P, Siegel L C, Parks R. et al . Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group.  Anesthesiology. 1998;  88 327-333
    CrossrefPubMedGoogle Scholar
  • 71 Surgenor D M, Churchill W H, Wallace E L. et al . The specific hospital significantly affects red cell and component transfusion practice in coronary artery bypass graft surgery: a study of five hospitals.  Transfusion. 1998;  38 122-134
    CrossrefPubMedGoogle Scholar
  • 72 Surgenor D M, Wallace E L, Churchill W H, Hao S H, Chapman R H, Collin-JJ J. Red cell transfusions in coronary artery bypass surgery.  Transfusion. 1992;  32 458-464
    CrossrefPubMedGoogle Scholar
  • 73 Surgenor D M, Wallace E L, Churchill W H, Hao S H, Chapman R H, Poss R. Red cell transfusions in total knee and total hip replacement surgery.  Transfusion. 1991;  31 531-537
    CrossrefPubMedGoogle Scholar
  • 74 Thomas L. Eisenstoffwechsel. In: Thomas L (Hrsg.) Labor und Diagnose.  Frankfurt/Main; TH-Books 1998: 275
    Google Scholar
  • 75 Thomas L. Hämatologie. In: Thomas L (Hrsg.) Labor und Diagnose.  Frankfurt/Main; TH-Books 1998: 475
    Google Scholar
  • 76 Toy P TCY, Kaplan E B, McVay P A, Lee S J, Strauss R G, Stehling L C. Blood loss and replacement in total hip arthroplasty: a multicenter study. The Preoperative Autologous Blood Donation Study Group.  Transfusion. 1992;  32 63-67
    CrossrefPubMedGoogle Scholar
  • 77 Toy P TCY, Strauss R G, Stehling L C. et al . Predeposited autologous blood for elective surgery. A national multicenter study.  N Engl J Med. 1987;  316 517-520
    PubMedGoogle Scholar
  • 78 Tryba M. Epoetin alfa plus autologous blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery.  Semin Hematol. 1996;  33 22-26
    PubMedGoogle Scholar
  • 79 Vamvakas E C. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials.  Transfusion. 1996;  36 175-186
    CrossrefPubMedGoogle Scholar
  • 80 van de Watering L MG, Hermans J, Houbiers J GA. et al . Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial.  Circulation. 1998;  97 562-568
    PubMedGoogle Scholar
  • 81 Wagner F F, Flegel W A, Kubanek B. Blood transfusion: influence of transfusion on outcome.  Curr Opin Anaesthesiol. 1998;  11 167-175
    CrossrefPubMedGoogle Scholar
  • 82 Warner D O, Warner M A, Schroeder D R, Offord K P, Maxson P, Santrach P. Changing transfusion practices in hip and knee arthroplasty.  Transfusion. 1998;  38 738-744
    CrossrefPubMedGoogle Scholar
  • 83 Williams J G, Hughes L E. Effect of perioperative blood transfusion on recurrence of Crohn's disease.  Lancet. 1989;  2 1524
    PubMedGoogle Scholar
  • 84 Richtlinien zur Blutgruppenbestimmung und Bluttransfusion (Hämotherapie).  Köln; Deutscher Ärzte-Verlag GmbH 1996
    Google Scholar

Dr. med. K. Buttenschoen

Chirurgische Klinik I
Universität Ulm

Steinhövelstraße 9

89075 Ulm

Phone: 0731/5027206

Fax: 0731/5027214

Email: klaus.buttenschoen@medizin.uni-ulm.de

      >